Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02798107
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
- Conditions
- Alzheimer Disease
- Interventions
- Drug: BI 425809 dose 1Drug: BI 425809 dose 2Drug: BI 425809 dose 3Drug: BI 425809 dose 4Drug: Placebo
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 611
- Registration Number
- NCT02788513
- Locations
- 🇬🇧
Fulbourn Hospital, Cambridge, United Kingdom
🇨🇦Diex Recherche, Sherbrooke, Quebec, Canada
🇦🇹LKH-Univ. Hospital Graz, Graz, Austria
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 347
- Registration Number
- NCT02788474
- Locations
- 🇨🇿
University Hospital Plzen, Plzen-Bory, Plzen, Czechia
🇧🇪Edegem - UNIV UZ Antwerpen, Edegem, Belgium
🇯🇵Kindai University Hospital, Osaka, Osakasayama, Japan
Anticoagulants Comparative Benefit-risk Ratio in Real Life
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103101
- Registration Number
- NCT02785354
- Locations
- 🇫🇷
1160.263.1 Boehringer Ingelheim Investigational Site, Multiple Locations, France
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02783040
- Locations
- 🇩🇪
1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02782624
- Locations
- 🇩🇪
1276.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1
- Registration Number
- NCT02780700
- Locations
- 🇺🇸
Fort Wayne Medical Oncology Hematology, Fort Wayne, Indiana, United States
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT02780687
- Locations
- 🇮🇹
A.O. San Camillo Forlanini, Roma, Italy
🇫🇷HOP Foch, Suresnes, France
🇫🇷INS Bergonié, Bordeaux, France
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 123
- Registration Number
- NCT02776683
- Locations
- 🇺🇦
Sumy Regional Oncology Center, Sumy, Ukraine
🇺🇸The Oncology Institute of Hope and Innovation, Anaheim, California, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Drug: BI 655064 dose 1Drug: BI 655064 dose 2Drug: BI 655064 dose 3Drug: Placebo
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT02770170
- Locations
- 🇺🇸
Feinstein Institute for Medical Research, Manhasset, New York, United States
🇵🇹Hospital Curry Cabral, EPE, Lisboa, Portugal
🇷🇸Institute of Rheumatology, Belgrade, Belgrade, Serbia